A pilot randomized controlled trial comparing a novel compassion and metacognition approach for schizotypal personality disorder with a combination of cognitive therapy and psychopharmacological treatment
dc.contributor.author | Cheli, Simone | |
dc.contributor.author | Cavalletti, Veronica | |
dc.contributor.author | Lysaker, Paul H. | |
dc.contributor.author | Dimaggio, Giancarlo | |
dc.contributor.author | Petrocchi, Nicola | |
dc.contributor.author | Chiarello, Francesca | |
dc.contributor.author | Enzo, Consuelo | |
dc.contributor.author | Velicogna, Francesco | |
dc.contributor.author | Mancini, Francesco | |
dc.contributor.author | Goldzweig, Gil | |
dc.contributor.department | Psychiatry, School of Medicine | |
dc.date.accessioned | 2023-10-31T10:17:38Z | |
dc.date.available | 2023-10-31T10:17:38Z | |
dc.date.issued | 2023-02-20 | |
dc.description.abstract | Background: Schizotypal personality disorder is characterized by a pervasive pattern of maladaptive behavior that has been associated with the liability for schizophrenia. Little is known about effective psychosocial interventions. This pilot non-inferiority randomized controlled trial aimed to compare a novel form of psychotherapy tailored for this disorder and a combination of cognitive therapy and psychopharmacological treatment. The former treatment - namely, Evolutionary Systems Therapy for Schizotypy-integrated evolutionary, metacognitively oriented, and compassion focused approaches. Methods: Thirty-three participants were assessed for eligibility, twenty-four randomized on a 1:1 ratio, nineteen included in the final analysis. The treatments lasted 6 months (24 sessions). The primary outcome was change across nine measurements in personality pathology, the secondary outcomes were remission from diagnosis and pre-post changes in general symptomatology and metacognition. Results: Primary outcome suggested a non-inferiority of the experimental treatment in respect to control condition. Secondary outcomes reported mixed results. There was no significant difference in terms of remission, but experimental treatment showed a larger reduction of general symptomatology (η2 = 0.558) and a larger increase in metacognition (η2 = 0.734). Conclusions: This pilot study reported promising results about the effectiveness of the proposed novel approach. A confirmatory trial on large sample size is needed to provide evidence about relative effectiveness of the two treatment conditions. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Cheli S, Cavalletti V, Lysaker PH, et al. A pilot randomized controlled trial comparing a novel compassion and metacognition approach for schizotypal personality disorder with a combination of cognitive therapy and psychopharmacological treatment. BMC Psychiatry. 2023;23(1):113. Published 2023 Feb 20. doi:10.1186/s12888-023-04610-5 | |
dc.identifier.uri | https://hdl.handle.net/1805/36785 | |
dc.language.iso | en_US | |
dc.publisher | BMC | |
dc.relation.isversionof | 10.1186/s12888-023-04610-5 | |
dc.relation.journal | BMC Psychiatry | |
dc.rights | Attribution 4.0 International | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | PMC | |
dc.subject | Compassion | |
dc.subject | Evolution | |
dc.subject | Evolutionary systems therapy for schizotypy | |
dc.subject | Metacognition | |
dc.subject | Schizotypal personality disorder | |
dc.subject | Schizotypy | |
dc.title | A pilot randomized controlled trial comparing a novel compassion and metacognition approach for schizotypal personality disorder with a combination of cognitive therapy and psychopharmacological treatment | |
dc.type | Article |